159 related articles for article (PubMed ID: 16569843)
1. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2006 Apr; 50(4):1293-7. PubMed ID: 16569843
[TBL] [Abstract][Full Text] [Related]
2. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
[TBL] [Abstract][Full Text] [Related]
3. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
Barchiesi F; Spreghini E; Tomassetti S; Della Vittoria A; Arzeni D; Manso E; Scalise G
Antimicrob Agents Chemother; 2006 Aug; 50(8):2719-27. PubMed ID: 16870764
[TBL] [Abstract][Full Text] [Related]
4. Caspofungin in combination with amphotericin B against Candida parapsilosis.
Barchiesi F; Spreghini E; Tomassetti S; Giannini D; Scalise G
Antimicrob Agents Chemother; 2007 Mar; 51(3):941-5. PubMed ID: 17158939
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Gumbo T; Drusano GL; Liu W; Kulawy RW; Fregeau C; Hsu V; Louie A
Antimicrob Agents Chemother; 2007 Mar; 51(3):968-74. PubMed ID: 17194830
[TBL] [Abstract][Full Text] [Related]
7. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Louie A; Deziel M; Liu W; Drusano MF; Gumbo T; Drusano GL
Antimicrob Agents Chemother; 2005 Dec; 49(12):5058-68. PubMed ID: 16304173
[TBL] [Abstract][Full Text] [Related]
10. Efficacies of caspofungin and a combination of caspofungin and meropenem in the treatment of murine disseminated candidiasis.
Ozcan SK; Budak F; Willke A; Filiz S; Costur P; Dalcik H
APMIS; 2006 Dec; 114(12):829-36. PubMed ID: 17207082
[TBL] [Abstract][Full Text] [Related]
11. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
Abruzzo GK; Flattery AM; Gill CJ; Kong L; Smith JG; Pikounis VB; Balkovec JM; Bouffard AF; Dropinski JF; Rosen H; Kropp H; Bartizal K
Antimicrob Agents Chemother; 1997 Nov; 41(11):2333-8. PubMed ID: 9371329
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
Kartsonis N; Killar J; Mixson L; Hoe CM; Sable C; Bartizal K; Motyl M
Antimicrob Agents Chemother; 2005 Sep; 49(9):3616-23. PubMed ID: 16127030
[TBL] [Abstract][Full Text] [Related]
14. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature.
Bacak V; Biocina B; Starcevic B; Gertler S; Begovac J
J Infect; 2006 Jul; 53(1):e11-4. PubMed ID: 16274746
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
Wiederhold NP; Najvar LK; Bocanegra R; Molina D; Olivo M; Graybill JR
Antimicrob Agents Chemother; 2007 May; 51(5):1616-20. PubMed ID: 17307976
[TBL] [Abstract][Full Text] [Related]
16. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis.
Lazzell AL; Chaturvedi AK; Pierce CG; Prasad D; Uppuluri P; Lopez-Ribot JL
J Antimicrob Chemother; 2009 Sep; 64(3):567-70. PubMed ID: 19584104
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.
Stevens DA; Espiritu M; Parmar R
Antimicrob Agents Chemother; 2004 Sep; 48(9):3407-11. PubMed ID: 15328104
[TBL] [Abstract][Full Text] [Related]
18. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.
Goldblum D; Frueh BE; Sarra GM; Katsoulis K; Zimmerli S
Antimicrob Agents Chemother; 2005 Apr; 49(4):1359-63. PubMed ID: 15793112
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin in combination with amphotericin B against Candida glabrata.
Barchiesi F; Spreghini E; Fothergill AW; Arzeni D; Greganti G; Giannini D; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2005 Jun; 49(6):2546-9. PubMed ID: 15917570
[TBL] [Abstract][Full Text] [Related]
20. Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology.
Szilágyi J; Földi R; Bayegan S; Kardos G; Majoros L
J Chemother; 2012 Feb; 24(1):18-25. PubMed ID: 22546720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
